Home  /  Resource Library  /  Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open Label, Single Arm, Phase II Trial

Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open Label, Single Arm, Phase II Trial

Results of a study investigating ibrutinib combined with rituximab for indolent mantle cell lymphoma.